<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898235</url>
  </required_header>
  <id_info>
    <org_study_id>H-22838</org_study_id>
    <secondary_id>CDR0000632869</secondary_id>
    <nct_id>NCT00898235</nct_id>
  </id_info>
  <brief_title>Collection of Samples and Clinical Data From Patients With Amyloid Diseases</brief_title>
  <official_title>Data, Tissue, Blood, and Urine Repository for Amyloid Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with
      amyloid diseases to test in the laboratory may help the study of this disease in the future.

      PURPOSE: This research study is collecting samples from patients with amyloid diseases
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To establish and maintain a database of clinical material (i.e., blood, urine, and
           tissue) and information on patients with amyloid diseases.

      OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard
      laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid Research
      Laboratory, to permit the correlation of clinical results with measured biological events,
      and for future research studies. Bone marrow RNA samples are examined for immunoglobulin
      light-chain gene sequences and amino acids by polymerase chain reaction and positional
      cloning. Blood serum and urine samples are evaluated for amyloid protein stability by
      high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-UV circular
      dichroism and fluorescence spectroscopy. Urine samples are also examined for
      post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to
      identify common features unique to amyloid proteins. Tissue samples are analyzed for
      biochemical and biophysical properties and for post-translational modifications in light
      chains.

      Quality of life is assessed by the 36-Item Short Form Survey (SF-36).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2000</start_date>
  <completion_date type="Anticipated">February 2037</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Establish a repository to promote biochemical research</measure>
    <time_frame>life of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collection of clinical material and information</measure>
    <time_frame>life of study</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>clonality analysis</intervention_name>
    <description>analyze clonality</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>analyze polymerase chain reaction</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>protein analysis</intervention_name>
    <description>analyze protein</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>biologic sample preservation procedure</intervention_name>
    <description>preserve biologic samples</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>analyze laboratory biomarkers</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>fluorescence spectroscopy</intervention_name>
    <description>perform fluorescence spectroscopy on specimens</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>assess quality of life at each follow-up for life</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, and tissue
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed, or with suspicion of having, amyloidosis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis or suspicion of amyloidosis

        PATIENT CHARACTERISTICS:

          -  Referred to the Amyloid Treatment and Research Center at Boston University Medical
             Center

        PRIOR CONCURRENT THERAPY:

          -  Not specified

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaishali Sanchorawala, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salli Fennessey</last_name>
    <phone>617-638-8261</phone>
    <email>sally.fennessey@bmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston University Cancer Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Boston University Cancer Research Cen</last_name>
      <phone>617-638-8265</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Medical Center</investigator_affiliation>
    <investigator_full_name>Vaishali Sanchorawala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>primary systemic amyloidosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

